Certara Selected by the European Medicines Agency to Provide Real World Solutions for Critical Regulatory Decisions
Princeton, N.J., March 17, 2022 -- Certara, Inc. today announced a four-year, framework service contract…
CertaraMarch 17, 2022
New PMDA Validation Rules 3.0 Explained
In this blog, we explore what you need to know about the update to the…
CertaraMarch 2, 2022
The Challenging Road to Developing an Integrated Platform for Drug Discovery and Precision Medicine Using the Power of Pharmacometrics
We have often seen Dr. Hwi-yeol (Thomas) Yun, Associate Professor/Adjunct Professor at the College of…
CertaraFebruary 7, 2022
What is the FDA’s Project Optimus & How Will it Affect Oncology Drug Development?
Project Optimus is an initiative proposed by the U.S. Food and Drug Administration’s Oncology Center…
CertaraFebruary 2, 2022
Improved Workflow and Expanded functionality of RsNLME v1.1
R Speaks NLME (RsNLME) is a collection of R packages and companion RShiny apps that…
CertaraJanuary 31, 2022
Choosing an eCTD Submissions Vendor: Your Complete Checklist
September 3, 2025 Selecting the right electronic submission vendor for regulatory submissions to health authorities…
CertaraJanuary 28, 2022
Don’t Forget About Safety! How to Assess Drug Candidate Safety in Early Clinical Development
This blog will reflect on 3 things drug developers should pay attention to regarding safety…
CertaraJanuary 24, 2022
Certara’s Simcyp® Simulator Demo
The Simcyp PBPK Simulator is the industry leader and most widely adopted platform for PBPK…
CertaraJanuary 20, 2022
